EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Acyclic Retinoid Attenuates STAT3 Signaling and Reduces In Vitro Growth of A375-Derived Dabrafenib Plus Trametinib-Resistant Melanoma Cells

Mitsuaki Nishizawa, Masanori Kimura, Hinata Hamada, Ichiro Yajima iD

International Journal of Molecular Sciences · 14.07.2026 · 27 (14) · 6245

DOI: 10.3390/ijms27146245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.07.2026. Verfasst von Mitsuaki Nishizawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, Fukasaku 307, Minuma-ku, Sait…. Hauptthemen laut MEDLINE: Imidazoles, Oximes, Pyridones, Drug Resistance, Neoplasm. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to combined BRAF and MEK inhibition remains a major barrier to durable disease control in BRAF-mutant melanoma. Acyclic retinoid (ACR; peretinoin) is a clinically studied retinoid, but its activity in MAPK inhibitor-resistant melanoma remains incompletely defined. Here, we established A375P-derived dabrafenib plus trametinib-resistant clones and evaluated ACR mainly in the A375PDTR-D clone as an in vitro proof-of-concept model. Resistant clones retained higher viability and failed to suppress ERK phosphorylation under dabrafenib plus trametinib treatment. In A375PDTR-D cells, ACR reduced short-term viability and clonogenic growth and was associated with decreased STAT3 Tyr705 phosphorylation, reduced EGFR, Cyclin D1, and Cyclin B1 expression, and increased p27KIP1. ACR did not detectably suppress AKT, MEK/ERK, or basal JNK phosphorylation under the tested conditions. These findings support further investigation of ACR as a candidate non-MAPK adjunct strategy; however, generalizability to broader melanoma models, formal drug-interaction status, direct cell-cycle/apoptosis effects, clinically achievable exposure, and in vivo efficacy remain to be established.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImidazolesOximesPyridonesDrug Resistance, NeoplasmMelanomaPyrimidinonesSTAT3 Transcription FactorSignal TransductionRetinoidsHumansCell Line, TumorCell ProliferationPhosphorylationCell Survival

Stichwörter der Autor:innen

Cyclin D1EGFRSTAT3acyclic retinoiddabrafenibdrug resistancemelanomap27KIP1peretinointrametinib

Substanzen

ImidazolesOximesPyridonesdabrafenibtrametinibPyrimidinonesSTAT3 Transcription FactorRetinoids

Autor:innen und Institutionen

  • Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, Fukasaku 307, Minuma-ku, Saitama 337-8570, Japan.

ORCID-Profile: Ichiro Yajima

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology

Zitieren

APA

Nishizawa, M., Kimura, M., Hamada, H., & Yajima, I. (2026). Acyclic Retinoid Attenuates STAT3 Signaling and Reduces In Vitro Growth of A375-Derived Dabrafenib Plus Trametinib-Resistant Melanoma Cells. International Journal of Molecular Sciences, 27(14), 6245. https://doi.org/10.3390/ijms27146245

Vancouver

Nishizawa M, Kimura M, Hamada H, Yajima I. Acyclic Retinoid Attenuates STAT3 Signaling and Reduces In Vitro Growth of A375-Derived Dabrafenib Plus Trametinib-Resistant Melanoma Cells. International Journal of Molecular Sciences. 2026;27(14):6245. doi:10.3390/ijms27146245

BibTeX
@article{Nishizawa2026,
  author = {Nishizawa, Mitsuaki and Kimura, Masanori and Hamada, Hinata and Yajima, Ichiro},
  title = {Acyclic Retinoid Attenuates STAT3 Signaling and Reduces In Vitro Growth of A375-Derived Dabrafenib Plus Trametinib-Resistant Melanoma Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {14},
  pages = {6245},
  doi = {10.3390/ijms27146245}
}
Kostenlos starten →